30 days ago
President Donald Trump used an anti-trans slur Monday to attack the Democratic nominee for the Senate in South Carolina as he urged voters to back Republican Sen. Darline Graham.
In a Truth Social post, Trump referred to Democratic candidate Annie Andrews three times as “trannie.” He said Andrews, who is not transgender, is “not for South Carolina.”
“And South Carolina must show, in the upcoming Election, that it is not for her,” Trump added.
Andrews responded by largely ignoring the insult, saying in a statement first shared with NBC News that she will “work with anyone to put South Carolina first.”
“As a mom and a pediatrician, I’m in this race to fight for my patients, my three kids, and South Carolina,” Andrews said, adding that “lowering costs and making life better for families across our state is going to take all of us working together.”
#Trump
In a Truth Social post, Trump referred to Democratic candidate Annie Andrews three times as “trannie.” He said Andrews, who is not transgender, is “not for South Carolina.”
“And South Carolina must show, in the upcoming Election, that it is not for her,” Trump added.
Andrews responded by largely ignoring the insult, saying in a statement first shared with NBC News that she will “work with anyone to put South Carolina first.”
“As a mom and a pediatrician, I’m in this race to fight for my patients, my three kids, and South Carolina,” Andrews said, adding that “lowering costs and making life better for families across our state is going to take all of us working together.”
#Trump
2 months ago
On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
2 months ago
Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function.
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.
#revenue #NASDAQ #joenja #pediatric
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.
#revenue #NASDAQ #joenja #pediatric
2 months ago
Leading U.S. medical groups are urging people to get updated flu and COVID-19 vaccinations this fall, banding together Wednesday to issue shot guidelines — and highlight the science behind them — saying they hope to ease confusion caused by the Trump administration's changing advice.
Flu vaccinations are beginning and COVID-19 shots are starting to arrive after the Food and Drug Administration approved this year's updated versions last week. Winter also brings another vaccine-preventable risk called RSV. Exactly who should get one or all of these vaccines, and when?
That advice usually comes from the Centers for Disease Control and Prevention, with help from its independent advisers. But despite no new scientific evidence, Trump health officials last year began pulling back on some longstanding recommendations for fall virus protection and routine children's vaccinations. And that advisory panel, which influences state and insurance vaccine policies, is caught in a court battle. The CDC didn't respond to questions about any new fall guidance but suggested on its website that doctors follow last year's flu recommendations.
Doctors' groups are filling the gap: the American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America each released vaccination guidelines for their patient populations.
"There's been a lot of confusion and chaos regarding vaccine recommendations," said Dr. Sandra Fryhofer, of the American Medical **** ociation.
#vaccinations #medical
Flu vaccinations are beginning and COVID-19 shots are starting to arrive after the Food and Drug Administration approved this year's updated versions last week. Winter also brings another vaccine-preventable risk called RSV. Exactly who should get one or all of these vaccines, and when?
That advice usually comes from the Centers for Disease Control and Prevention, with help from its independent advisers. But despite no new scientific evidence, Trump health officials last year began pulling back on some longstanding recommendations for fall virus protection and routine children's vaccinations. And that advisory panel, which influences state and insurance vaccine policies, is caught in a court battle. The CDC didn't respond to questions about any new fall guidance but suggested on its website that doctors follow last year's flu recommendations.
Doctors' groups are filling the gap: the American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America each released vaccination guidelines for their patient populations.
"There's been a lot of confusion and chaos regarding vaccine recommendations," said Dr. Sandra Fryhofer, of the American Medical **** ociation.
#vaccinations #medical
2 months ago
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of new abnormal bone lesions by 94% compared with placebo. The decision completed an unusual clinical recovery. Regeneron paused an earlier study in 2020 after five patients died during its open-label portion, when all participants were receiving active treatment. The published ****** ysis later considered a relationship to treatment unlikely, although causality could not be ruled out. For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pasatru is a regulatory and scientific victory whose earnings potential is constrained by an exceptionally small market.
The company's existing scale makes that limitation difficult to ignore. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) generated second-quarter revenue of $4.29 billion, up 17%, while company-defined non-GAAP diluted EPS reached $14.29. Global Dupixent sales, recorded by partner Sanofi, increased 38% to approximately $6 billion, and U.S. Eylea HD sales rose 52% to $596 million. Against those franchises, even a successful Pasatru launch would have limited influence on consolidated results.
The approval demonstrates that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) can recover a program after a major clinical setback. Following the 2020 dosing pause, the company worked with regulators to design a late-stage study that produced a statistically significant reduction in new bone lesions. Pasatru also validates research into Activin A, which activates the mutant ACVR1/ALK2 receptor and triggers abnormal bone formation in FOP.
That platform value may matter more than initial sales. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) plans to begin a pediatric trial later in 2026, which could eventually expand the eligible population. The regulatory recovery may also strengthen confidence in the company's ability to advance other rare-disease programs from internally discovered biology.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is entering an exceptionally small pharmaceutical market. Published prevalence estimates generally range from approximately one case per one million to one per two million people. Only approximately 800 to 900 known or confirmed cases have been identified globally, although additional patients may remain undiagnosed. Pasatru is currently approved only for adults, further narrowing its immediate market.
#regeneron #pasatru #adults #market
The company's existing scale makes that limitation difficult to ignore. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) generated second-quarter revenue of $4.29 billion, up 17%, while company-defined non-GAAP diluted EPS reached $14.29. Global Dupixent sales, recorded by partner Sanofi, increased 38% to approximately $6 billion, and U.S. Eylea HD sales rose 52% to $596 million. Against those franchises, even a successful Pasatru launch would have limited influence on consolidated results.
The approval demonstrates that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) can recover a program after a major clinical setback. Following the 2020 dosing pause, the company worked with regulators to design a late-stage study that produced a statistically significant reduction in new bone lesions. Pasatru also validates research into Activin A, which activates the mutant ACVR1/ALK2 receptor and triggers abnormal bone formation in FOP.
That platform value may matter more than initial sales. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) plans to begin a pediatric trial later in 2026, which could eventually expand the eligible population. The regulatory recovery may also strengthen confidence in the company's ability to advance other rare-disease programs from internally discovered biology.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is entering an exceptionally small pharmaceutical market. Published prevalence estimates generally range from approximately one case per one million to one per two million people. Only approximately 800 to 900 known or confirmed cases have been identified globally, although additional patients may remain undiagnosed. Pasatru is currently approved only for adults, further narrowing its immediate market.
#regeneron #pasatru #adults #market
2 months ago
General Hospital star Sawandi Wilson is one proud dad. After revealing the harrowing story of his new baby's birth last week, Wilson is happy to report that his little girl is home and doing well — and she even has a name.
"THE LEGEND OF: ZELDA DANA EILINSFELD WILSON," the actor wrote on Instagram on the morning of August 24th, alongside a series of photos of himself and his wife, Anna Eilinsfeld, with their baby. "5 days in the NICU.✅ Pediatric appointments. ✅ Checking out of the hospital with a clean bill of health…PRICELESS."
Wilson had taken to social media a week earlier to tell the story of his daughter's emergency C-section birth. A few days later, he updated fans on Zelda's condition and the first moment he had laid eyes on her in the NICU.
"The first time we see our daughter — like, technically, the first, day one of being a dad — she's hooked up to machines to help her breathe," Wilson explained in an Instagram video. "She's hooked up to machines to help stabilize her glucose levels."
Although Wilson asked himself why this was happening to his family, looking around the NICU helped put things in perspective for the proud, new dad.
#first #Instagram
"THE LEGEND OF: ZELDA DANA EILINSFELD WILSON," the actor wrote on Instagram on the morning of August 24th, alongside a series of photos of himself and his wife, Anna Eilinsfeld, with their baby. "5 days in the NICU.✅ Pediatric appointments. ✅ Checking out of the hospital with a clean bill of health…PRICELESS."
Wilson had taken to social media a week earlier to tell the story of his daughter's emergency C-section birth. A few days later, he updated fans on Zelda's condition and the first moment he had laid eyes on her in the NICU.
"The first time we see our daughter — like, technically, the first, day one of being a dad — she's hooked up to machines to help her breathe," Wilson explained in an Instagram video. "She's hooked up to machines to help stabilize her glucose levels."
Although Wilson asked himself why this was happening to his family, looking around the NICU helped put things in perspective for the proud, new dad.
#first #Instagram
3 months ago
On August 13, Aveanna Healthcare (NASDAQ:AVAH) held its second-quarter earnings call, and the tone was different from prior quarters spent explaining away a caregiver shortage. Revenue climbed 13.7% year over year to roughly $670 million, and every one of the company's three divisions grew. But the headline moment came when CEO Jeffrey Shaner announced that California's 2027 budget will finally include a meaningful pediatric private duty nursing rate increase, effective January 1, 2027, closing out an advocacy push that took four years and now touches all 32 of Aveanna's private duty states.
Aveanna's core strategy for the past several years has been aligning caregiver capacity with the payers willing to pay for it, and the numbers on the call suggest that bet is paying off. Home health and hospice revenue rose 14.8% year over year, private duty services grew 14.0%, and medical solutions added 9.4%, with adjusted EBITDA up 8% to $95.4 million. On the government side, Aveanna landed seven state rate enhancements by the second quarter and expects more once state budget processes wrap up in the third quarter, with California standing as the biggest prize of all. On the payer side, private duty services now has 37 preferred payer agreements after adding three in the quarter, and those agreements cover 64% of the division's managed care volume, up from 60% in the first quarter. Home health has already hit its full-year goal of 50 preferred payers, with episodic admissions running at 81% of the mix and episodic volume growth of 18.5%.
Management also pointed to CMS's proposed home health rule, published July 1, and its finalized hospice rule, published August 6, as supportive of stable industry rates. Layered on top is the Family First Homecare acquisition, closed in early June and on track to finish integrating by late in the fourth quarter, plus guidance raised to more than $2.68 billion in revenue and more than $365 million in adjusted EBITDA for the year.
Not every figure on the call moved in the company's favor. Private duty services revenue per hour rose just 1.7% to $44.62, while the segment's cost of revenue per hour jumped 7.8% to $31.74, and the spread per hour landed at $12.88 as caregiver wage increases continue working their way through the business. Management also noted that the year-ago quarter in that same segment included about $9 million in nonrecurring favorable items, which makes the current growth rate a harder comparison than it first appears. Much of the good news still depends on government timing that Aveanna does not control: the California rate increase is pending final details from the Medi-Cal department, and additional state wins hinge on budget cycles still playing out. The Family First Homecare deal was funded entirely out of cash on hand, and its integration is not expected to finish until late in the fourth quarter, so the returns on that spending have not fully shown up yet.
#quarter #private #duty #rate
Aveanna's core strategy for the past several years has been aligning caregiver capacity with the payers willing to pay for it, and the numbers on the call suggest that bet is paying off. Home health and hospice revenue rose 14.8% year over year, private duty services grew 14.0%, and medical solutions added 9.4%, with adjusted EBITDA up 8% to $95.4 million. On the government side, Aveanna landed seven state rate enhancements by the second quarter and expects more once state budget processes wrap up in the third quarter, with California standing as the biggest prize of all. On the payer side, private duty services now has 37 preferred payer agreements after adding three in the quarter, and those agreements cover 64% of the division's managed care volume, up from 60% in the first quarter. Home health has already hit its full-year goal of 50 preferred payers, with episodic admissions running at 81% of the mix and episodic volume growth of 18.5%.
Management also pointed to CMS's proposed home health rule, published July 1, and its finalized hospice rule, published August 6, as supportive of stable industry rates. Layered on top is the Family First Homecare acquisition, closed in early June and on track to finish integrating by late in the fourth quarter, plus guidance raised to more than $2.68 billion in revenue and more than $365 million in adjusted EBITDA for the year.
Not every figure on the call moved in the company's favor. Private duty services revenue per hour rose just 1.7% to $44.62, while the segment's cost of revenue per hour jumped 7.8% to $31.74, and the spread per hour landed at $12.88 as caregiver wage increases continue working their way through the business. Management also noted that the year-ago quarter in that same segment included about $9 million in nonrecurring favorable items, which makes the current growth rate a harder comparison than it first appears. Much of the good news still depends on government timing that Aveanna does not control: the California rate increase is pending final details from the Medi-Cal department, and additional state wins hinge on budget cycles still playing out. The Family First Homecare deal was funded entirely out of cash on hand, and its integration is not expected to finish until late in the fourth quarter, so the returns on that spending have not fully shown up yet.
#quarter #private #duty #rate
3 months ago
Caitlin Clark launches heartfelt hospital program for pediatric patients originally appeared on The Sporting News. Add The Sporting News as a Preferred Source by clicking here.
Caitlin Clark has built her basketball career by creating opportunities for teammates. Her newest **** ist will deliver books, activities and moments of happiness to children facing much more difficult circumstances than anything encountered on a basketball court.
The Caitlin Clark Foundation announced the launch of "Turning Pages, Healing Hearts," a new program designed to support pediatric patients and their families at children's hospitals in Indiana and Iowa. Created in partnership with Scholastic, the initiative provides participating hospitals with book vending machines and tokens that allow young patients to select books based on their own interests. The program also includes arts and crafts activities and a welcome "joy finder."
"We are honored to be bringing our new program, Turning Pages, Healing Hearts, to local hospitals!" the foundation announced on Instagram.
Clark shared the post on her Instagram Story and added an emotional response.
#clark #program #patients #healing
Caitlin Clark has built her basketball career by creating opportunities for teammates. Her newest **** ist will deliver books, activities and moments of happiness to children facing much more difficult circumstances than anything encountered on a basketball court.
The Caitlin Clark Foundation announced the launch of "Turning Pages, Healing Hearts," a new program designed to support pediatric patients and their families at children's hospitals in Indiana and Iowa. Created in partnership with Scholastic, the initiative provides participating hospitals with book vending machines and tokens that allow young patients to select books based on their own interests. The program also includes arts and crafts activities and a welcome "joy finder."
"We are honored to be bringing our new program, Turning Pages, Healing Hearts, to local hospitals!" the foundation announced on Instagram.
Clark shared the post on her Instagram Story and added an emotional response.
#clark #program #patients #healing
3 months ago
How to Watch 2026 WEEI/NESN Jimmy Fund Radio-Telethon: Full Coverage on on Aug. 17 & 18 originally appeared on NESN. Add NESN as a Preferred Source by clicking here.
The annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance is back.
Coverage of the event will be held across Monday, Aug. 17 and Tuesday, Aug. 18. The 24th annual fundraiser benefits the Jimmy Fund and directly supports adult and pediatric cancer care and research at Dana-Farber.
"This inspiring radio and television broadcast live from Fenway Park is an incredible way to bring together Red Sox fans and supporters to raise funds for Dana-Farber Cancer Institute and the Jimmy Fund. Tune in on Aug. 17 and 18 to hear inspirational patient stories and make a gift of any size to help strike out cancer," Jimmy Fund co-chairs Tom Caron and Brock Holt said.
"We look forward to celebrating stories of hope and support for cancer care and research at Dana-Farber."
#cancer
The annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance is back.
Coverage of the event will be held across Monday, Aug. 17 and Tuesday, Aug. 18. The 24th annual fundraiser benefits the Jimmy Fund and directly supports adult and pediatric cancer care and research at Dana-Farber.
"This inspiring radio and television broadcast live from Fenway Park is an incredible way to bring together Red Sox fans and supporters to raise funds for Dana-Farber Cancer Institute and the Jimmy Fund. Tune in on Aug. 17 and 18 to hear inspirational patient stories and make a gift of any size to help strike out cancer," Jimmy Fund co-chairs Tom Caron and Brock Holt said.
"We look forward to celebrating stories of hope and support for cancer care and research at Dana-Farber."
#cancer
3 months ago
Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth was primarily driven by a 48% increase in ZELSUVMI prescription units, reflecting strong market adoption of the first and only FDA-approved at-home treatment for Molluscum Contagiosum (MC).
Management attributes the 81.3% unit increase within a major PBM to a strategic contract executed late last year, which significantly reduced patient friction and accelerated prescriber acquisition.
The company achieved top-line growth while simultaneously improving operational efficiency, reducing wholesale inventory days on hand by approximately three days during the quarter.
Strategic positioning is bolstered by new expert consensus guidelines published in the Journal of Drugs in Dermatology, which recognize ZELSUVMI as the sole at-home clinical option for pediatric MC.
#strategic #increase #tell
Revenue growth was primarily driven by a 48% increase in ZELSUVMI prescription units, reflecting strong market adoption of the first and only FDA-approved at-home treatment for Molluscum Contagiosum (MC).
Management attributes the 81.3% unit increase within a major PBM to a strategic contract executed late last year, which significantly reduced patient friction and accelerated prescriber acquisition.
The company achieved top-line growth while simultaneously improving operational efficiency, reducing wholesale inventory days on hand by approximately three days during the quarter.
Strategic positioning is bolstered by new expert consensus guidelines published in the Journal of Drugs in Dermatology, which recognize ZELSUVMI as the sole at-home clinical option for pediatric MC.
#strategic #increase #tell
3 months ago
WASHINGTON (AP) — Public health experts have been quick to condemn an executive order from President Donald Trump aimed at upending childhood vaccinations in the U.S., but the biggest obstacles may be the unprecedented financial and logistical challenges it would impose on parents, health providers and drugmakers.
Monday's announcement by the Republican president calls for separating combination shots — including the measles, mumps and rubella, or MMR, vaccine — into separate injections. Appointments for that and other vaccinations should be ****** ed out whenever possible, the order states.
To accomplish that, drugmakers would need to revive a slate of individual vaccines that have not been widely used in the U.S. for decades. They would also have to build new manufacturing plants capable of producing millions more vaccine doses than the nation currently uses.
For parents, unbundling the MMR vaccine and ****** ing out the shots would mean returning to the doctor's office many more times than is currently needed. Those appointments could also strain pediatricians who typically administer the shots, while driving up costs tied to syringes and other medical supplies.
Studies in the U.S. and other countries have shown that combination vaccines increase the likelihood that children will be fully protected from infectious diseases before starting school.
#shots #Health #order #vaccinations
Monday's announcement by the Republican president calls for separating combination shots — including the measles, mumps and rubella, or MMR, vaccine — into separate injections. Appointments for that and other vaccinations should be ****** ed out whenever possible, the order states.
To accomplish that, drugmakers would need to revive a slate of individual vaccines that have not been widely used in the U.S. for decades. They would also have to build new manufacturing plants capable of producing millions more vaccine doses than the nation currently uses.
For parents, unbundling the MMR vaccine and ****** ing out the shots would mean returning to the doctor's office many more times than is currently needed. Those appointments could also strain pediatricians who typically administer the shots, while driving up costs tied to syringes and other medical supplies.
Studies in the U.S. and other countries have shown that combination vaccines increase the likelihood that children will be fully protected from infectious diseases before starting school.
#shots #Health #order #vaccinations
3 months ago
As part of their annual partnership with the University of Iowa Health Stead Family Children's Hospital, Iowa football revealed its list of Kid Captains for the 2026-27 season on Monday, Aug. 3.
The special partnership between the Iowa football program and the Stead Family Children's Hospital, which started in 2009, honors pediatric patients by celebrating and highlighting their incredible stories throughout the season as they receive care for their various medical conditions.
According to Monday's announcement, this year's Kid Captains roster includes 12 total names ****** igned to the following games:
Harlow Taube - Iowa vs. Northern Illinois, Sept. 5
Charlie Price - Iowa vs. Iowa State, Sept. 12
#family
The special partnership between the Iowa football program and the Stead Family Children's Hospital, which started in 2009, honors pediatric patients by celebrating and highlighting their incredible stories throughout the season as they receive care for their various medical conditions.
According to Monday's announcement, this year's Kid Captains roster includes 12 total names ****** igned to the following games:
Harlow Taube - Iowa vs. Northern Illinois, Sept. 5
Charlie Price - Iowa vs. Iowa State, Sept. 12
#family
3 months ago
Hey Creatorverse readers,
Amid all the chatter about brand deals and follower counts, the charitable side of creators is often overlooked. This past week, two major creators — MrBeast (510 million YouTube subscribers) and Jacksepticeye (31 million subscribers) — doubled down on giving back.
Though MrBeast and Jacksepticeye are the two creators making headlines right now, philanthropic efforts are baked into the work of many creators, partially because giveaways and community alignment are so core to the creator ecosystem. That focus has translated into an increase in donations from Millennial and Gen Z audiences as donations overall have declined.
MrBeast partnered with Disney and Stand Up to Cancer (SU2C) on "I Granted 100 Kids Their Biggest Wish!" a video that chronicled celebrities like MrBeast, Dwayne Johnson and LeBron James granting some of the biggest dreams to children who have been diagnosed with cancer. The goal of the video is to increase awareness for pediatric cancer and raise funds for research, which naturally includes an elaborate MrBeast giveaway for anyone who donates to the charity Give Kids The World. Since being posted on Sunday, the video has accumulated over 30 million views. Those views will only increase as the video remains on MrBeast's channel for the next six months.
"We've never had an opportunity like this to engage people all over the world, and certainly not through a creator platform at this scale. So, it's truly a 'first' for SU2C," Pam Williams, a member of the SU2C founders and advisors committee, told me. So far it's a strategy that's working. The video has been seen by people in 68 countries so far, and almost 90% of donators are supporting the organization for the first time.
#creators
Amid all the chatter about brand deals and follower counts, the charitable side of creators is often overlooked. This past week, two major creators — MrBeast (510 million YouTube subscribers) and Jacksepticeye (31 million subscribers) — doubled down on giving back.
Though MrBeast and Jacksepticeye are the two creators making headlines right now, philanthropic efforts are baked into the work of many creators, partially because giveaways and community alignment are so core to the creator ecosystem. That focus has translated into an increase in donations from Millennial and Gen Z audiences as donations overall have declined.
MrBeast partnered with Disney and Stand Up to Cancer (SU2C) on "I Granted 100 Kids Their Biggest Wish!" a video that chronicled celebrities like MrBeast, Dwayne Johnson and LeBron James granting some of the biggest dreams to children who have been diagnosed with cancer. The goal of the video is to increase awareness for pediatric cancer and raise funds for research, which naturally includes an elaborate MrBeast giveaway for anyone who donates to the charity Give Kids The World. Since being posted on Sunday, the video has accumulated over 30 million views. Those views will only increase as the video remains on MrBeast's channel for the next six months.
"We've never had an opportunity like this to engage people all over the world, and certainly not through a creator platform at this scale. So, it's truly a 'first' for SU2C," Pam Williams, a member of the SU2C founders and advisors committee, told me. So far it's a strategy that's working. The video has been seen by people in 68 countries so far, and almost 90% of donators are supporting the organization for the first time.
#creators
4 months ago
Fred Alger Management, an investment management company, released its "Alger Small Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) fueled market optimism in the quarter, driving the Information Technology and Industrials sectors forward while Energy and Utilities lagged due to falling oil and gas prices. In June, the Federal Reserve maintained steady interest rates, but the meeting had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified within sectors adopting the technology. The Alger Small Cap Focus Fund's Class A shares outperformed the Russell 2000 Growth Index in the quarter, driven by strong performances in the Industrials and Health Care sectors, while Financials and Consumer Discretionary detracted from the performance. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted GeneDx Holdings Corp. (NASDAQ:WGS). GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company that offers advanced exome and genome sequencing for pediatric and rare disease diagnostics. On July 20, 2026, GeneDx Holdings Corp. (NASDAQ:WGS) closed at $60.65 per share, reflecting a market capitalization of $1.80 billion. GeneDx Holdings Corp. (NASDAQ:WGS) posted a one-month return of 4.42%, while its shares lost 25.03% over the past 52 weeks.
Alger Small Cap Focus Fund stated the following regarding GeneDx Holdings Corp. (NASDAQ:WGS) in its Q2 2026 investor update:
"GeneDx Holdings Corp. (NASDAQ:WGS) is a specialty genomics laboratory focused on delivering complex genetic tests, including whole exome and genome sequencing, to diagnose pediatric rare diseases. The company possesses a comprehensive and proprietary database of genetic data that enables it to deliver superior diagnostic yields relative to competitors and alternative testing modalities, creating a meaningful competitive advantage in a highly specialized market. Shares detracted from performance after first-quarter results missed revenue expectations on softer average reimbursement rates and weakness in non-core segments. While underlying exome and genome test volumes grew 33% year over year, management lowered full-year guidance, weighing on investor sentiment."
#NASDAQ #small #focus #fund
In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted GeneDx Holdings Corp. (NASDAQ:WGS). GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company that offers advanced exome and genome sequencing for pediatric and rare disease diagnostics. On July 20, 2026, GeneDx Holdings Corp. (NASDAQ:WGS) closed at $60.65 per share, reflecting a market capitalization of $1.80 billion. GeneDx Holdings Corp. (NASDAQ:WGS) posted a one-month return of 4.42%, while its shares lost 25.03% over the past 52 weeks.
Alger Small Cap Focus Fund stated the following regarding GeneDx Holdings Corp. (NASDAQ:WGS) in its Q2 2026 investor update:
"GeneDx Holdings Corp. (NASDAQ:WGS) is a specialty genomics laboratory focused on delivering complex genetic tests, including whole exome and genome sequencing, to diagnose pediatric rare diseases. The company possesses a comprehensive and proprietary database of genetic data that enables it to deliver superior diagnostic yields relative to competitors and alternative testing modalities, creating a meaningful competitive advantage in a highly specialized market. Shares detracted from performance after first-quarter results missed revenue expectations on softer average reimbursement rates and weakness in non-core segments. While underlying exome and genome test volumes grew 33% year over year, management lowered full-year guidance, weighing on investor sentiment."
#NASDAQ #small #focus #fund
4 months ago
Those who know Dr. Myron Rolle aren't surprised by the trajectory of his life.
Or his latest endeavor.
The NFL Players ***** ociation announced Monday, July 6, that Rolle — one of the most accomplished student-athletes in Florida State history — has joined the union in strategic advisory roles focused on player health, brain cognition and preventive care throughout a player's life.
Rolle, who starred as a safety for the Seminoles from 2006-08 before earning a Rhodes Scholarship to study at Oxford University, is now a pediatric neurosurgeon and nationally recognized researcher.
The union said Rolle will lend his medical expertise to several NFLPA initiatives, including the Mackey-White Health and Safety Committee, helping shape efforts to protect players during and after their NFL careers.
Or his latest endeavor.
The NFL Players ***** ociation announced Monday, July 6, that Rolle — one of the most accomplished student-athletes in Florida State history — has joined the union in strategic advisory roles focused on player health, brain cognition and preventive care throughout a player's life.
Rolle, who starred as a safety for the Seminoles from 2006-08 before earning a Rhodes Scholarship to study at Oxford University, is now a pediatric neurosurgeon and nationally recognized researcher.
The union said Rolle will lend his medical expertise to several NFLPA initiatives, including the Mackey-White Health and Safety Committee, helping shape efforts to protect players during and after their NFL careers.
4 months ago
Former NFL safety Myron Rolle went to medical school after he completed his playing career and the pediatric neurosurgeon is now coming back to work with the NFL Players ******* ociation.
The NFLPA announced that Rolle will be joining the union as a strategic advisor. Rolle's work will focus on player health, brain cognition, and preventative care for active players.
“This sport gave my family joy, discipline, and community,” Rolle said in a statement. “To return now, as a physician, researcher and former player, and contribute to the wellbeing of the men who make this game what it is, feels deeply meaningful. I am honored to support the NFLPA’s mission and help advance a future where every player’s health is protected with the highest standard of care.”
Rolle was named a Rhodes Scholar while playing at Florida State and the ******* ans drafted him in the sixth round in 2010. He also spent time with the Steelers, but did not play in any regular season games before going back to Florida State for medical school in 2013.
The NFLPA announced that Rolle will be joining the union as a strategic advisor. Rolle's work will focus on player health, brain cognition, and preventative care for active players.
“This sport gave my family joy, discipline, and community,” Rolle said in a statement. “To return now, as a physician, researcher and former player, and contribute to the wellbeing of the men who make this game what it is, feels deeply meaningful. I am honored to support the NFLPA’s mission and help advance a future where every player’s health is protected with the highest standard of care.”
Rolle was named a Rhodes Scholar while playing at Florida State and the ******* ans drafted him in the sixth round in 2010. He also spent time with the Steelers, but did not play in any regular season games before going back to Florida State for medical school in 2013.
4 months ago
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Merck & Co., Inc. (NYSE:MRK) is one of the best weight loss drugs on this list.
TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its use to children and adolescents between 2 and 17 years old. The updated indication applies to pediatric patients who have completed their initial pneumococcal vaccination series and have chronic health conditions that increase their vulnerability to pneumococcal disease. With this authorization, Capvaxive becomes the only pneumococcal conjugate vaccine (PCV) in the United States specifically evaluated and approved for this patient group.
In another major operational breakthrough, on June 12, Merck & Co., Inc. (NYSE:MRK) announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA and KEYTRUDA QLEX, its anti-PD-1 therapies, in combination with WELIREG for the adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at an increased risk of recurrence after surgery. The approval marks the first use of WELIREG in earlier-stage ccRCC and the first authorization of a PD-1 and HIF-2α inhibitor combination therapy. The decision was supported by results from the Phase 3 LITESPARK-022 trial, which showed the combination reduced the risk of recurrence, metastasis, or death by 28% compared with KEYTRUDA plus placebo in eligible patients.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company expanding its obesity pipeline through early-stage GLP-1 and dual agonist therapies. While it lacks a marketed weight-loss drug, its metabolic research and strong pharmaceutical portfolio make it a potential long-term obesity market contender.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its use to children and adolescents between 2 and 17 years old. The updated indication applies to pediatric patients who have completed their initial pneumococcal vaccination series and have chronic health conditions that increase their vulnerability to pneumococcal disease. With this authorization, Capvaxive becomes the only pneumococcal conjugate vaccine (PCV) in the United States specifically evaluated and approved for this patient group.
In another major operational breakthrough, on June 12, Merck & Co., Inc. (NYSE:MRK) announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA and KEYTRUDA QLEX, its anti-PD-1 therapies, in combination with WELIREG for the adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at an increased risk of recurrence after surgery. The approval marks the first use of WELIREG in earlier-stage ccRCC and the first authorization of a PD-1 and HIF-2α inhibitor combination therapy. The decision was supported by results from the Phase 3 LITESPARK-022 trial, which showed the combination reduced the risk of recurrence, metastasis, or death by 28% compared with KEYTRUDA plus placebo in eligible patients.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company expanding its obesity pipeline through early-stage GLP-1 and dual agonist therapies. While it lacks a marketed weight-loss drug, its metabolic research and strong pharmaceutical portfolio make it a potential long-term obesity market contender.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
4 months ago
DexCom, Inc. (NASDAQ:DXCM) is one of the 12 High Quality Stocks to Buy for the Long Term.
On June 15, 2026, Piper Sandler **** yst Matt O'Brien raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $88 from $75 and maintained an Overweight rating on the shares. O'Brien said Piper Sandler updated some of its models to better align with quarterly cadence, company guidance, and consensus estimates. For DexCom, the firm cited greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth.
On June 12, 2026, the U.S. Food and Drug Administration cleared DexCom, Inc.'s (NASDAQ:DXCM) Stelo Glucose Biosensor System for marketing as the first over-the-counter continuous glucose monitor for children. The integrated CGM is indicated for people two years of age and older who do not use insulin. The FDA had previously cleared Stelo OTC for individuals 18 years and older in March 2024. Michelle Tarver, Director of the Center for Devices and Radiological Health, said the clearance reflects the FDA's commitment to supporting innovation for pediatric patients.
Pixabay/Public Domain
On June 10, 2026, TD Cowen **** yst Joshua Jennings raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $95 from $75 and maintained a Buy rating on the shares. Jennings said DexCom appears to be at the forefront of the T2NIT coverage expansion initiative and that CONNECT represents a compelling dataset for payers. TD Cowen views DexCom as a share gainer in the U.S. T2NIT market, while noting that incremental access should benefit all players because of the size of the opportunity.
On June 15, 2026, Piper Sandler **** yst Matt O'Brien raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $88 from $75 and maintained an Overweight rating on the shares. O'Brien said Piper Sandler updated some of its models to better align with quarterly cadence, company guidance, and consensus estimates. For DexCom, the firm cited greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth.
On June 12, 2026, the U.S. Food and Drug Administration cleared DexCom, Inc.'s (NASDAQ:DXCM) Stelo Glucose Biosensor System for marketing as the first over-the-counter continuous glucose monitor for children. The integrated CGM is indicated for people two years of age and older who do not use insulin. The FDA had previously cleared Stelo OTC for individuals 18 years and older in March 2024. Michelle Tarver, Director of the Center for Devices and Radiological Health, said the clearance reflects the FDA's commitment to supporting innovation for pediatric patients.
Pixabay/Public Domain
On June 10, 2026, TD Cowen **** yst Joshua Jennings raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $95 from $75 and maintained a Buy rating on the shares. Jennings said DexCom appears to be at the forefront of the T2NIT coverage expansion initiative and that CONNECT represents a compelling dataset for payers. TD Cowen views DexCom as a share gainer in the U.S. T2NIT market, while noting that incremental access should benefit all players because of the size of the opportunity.
5 months ago
DexCom, Inc. (NASDAQ:DXCM) is one of the 12 High Quality Stocks to Buy for the Long Term.
On June 15, 2026, Piper Sandler **** yst Matt O'Brien raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $88 from $75 and maintained an Overweight rating on the shares. O'Brien said Piper Sandler updated some of its models to better align with quarterly cadence, company guidance, and consensus estimates. For DexCom, the firm cited greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth.
On June 12, 2026, the U.S. Food and Drug Administration cleared DexCom, Inc.'s (NASDAQ:DXCM) Stelo Glucose Biosensor System for marketing as the first over-the-counter continuous glucose monitor for children. The integrated CGM is indicated for people two years of age and older who do not use insulin. The FDA had previously cleared Stelo OTC for individuals 18 years and older in March 2024. Michelle Tarver, Director of the Center for Devices and Radiological Health, said the clearance reflects the FDA's commitment to supporting innovation for pediatric patients.
Pixabay/Public Domain
On June 10, 2026, TD Cowen **** yst Joshua Jennings raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $95 from $75 and maintained a Buy rating on the shares. Jennings said DexCom appears to be at the forefront of the T2NIT coverage expansion initiative and that CONNECT represents a compelling dataset for payers. TD Cowen views DexCom as a share gainer in the U.S. T2NIT market, while noting that incremental access should benefit all players because of the size of the opportunity.
On June 15, 2026, Piper Sandler **** yst Matt O'Brien raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $88 from $75 and maintained an Overweight rating on the shares. O'Brien said Piper Sandler updated some of its models to better align with quarterly cadence, company guidance, and consensus estimates. For DexCom, the firm cited greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth.
On June 12, 2026, the U.S. Food and Drug Administration cleared DexCom, Inc.'s (NASDAQ:DXCM) Stelo Glucose Biosensor System for marketing as the first over-the-counter continuous glucose monitor for children. The integrated CGM is indicated for people two years of age and older who do not use insulin. The FDA had previously cleared Stelo OTC for individuals 18 years and older in March 2024. Michelle Tarver, Director of the Center for Devices and Radiological Health, said the clearance reflects the FDA's commitment to supporting innovation for pediatric patients.
Pixabay/Public Domain
On June 10, 2026, TD Cowen **** yst Joshua Jennings raised the firm's price target on DexCom, Inc. (NASDAQ:DXCM) to $95 from $75 and maintained a Buy rating on the shares. Jennings said DexCom appears to be at the forefront of the T2NIT coverage expansion initiative and that CONNECT represents a compelling dataset for payers. TD Cowen views DexCom as a share gainer in the U.S. T2NIT market, while noting that incremental access should benefit all players because of the size of the opportunity.
5 months ago
Ms. Rachel is turning her attention to the conflict in the Middle East.
Days after the famed YouTube personality, 43, addressed followers from the United States Capitol as she continues to speak out for children affected by President Donald Trump's immigration crackdown, she shared information about a doctor reportedly held in solitary confinement.
"Free Dr. Hussam Abu Safiya. He is a pediatrician," she wrote in an Instagram post shared Thursday, June 18.
"His life's work has been caring for children," she continued. "He refused to abandon the babies, toddlers and children under his care during a genocide."
Earlier this week, Israel's Supreme Court rejected an appeal from the prominent Palestinian doctor, who is being held under the Unlawful Combatants Law without any criminal charges against him in Israel, according to Al Jazeera.
Days after the famed YouTube personality, 43, addressed followers from the United States Capitol as she continues to speak out for children affected by President Donald Trump's immigration crackdown, she shared information about a doctor reportedly held in solitary confinement.
"Free Dr. Hussam Abu Safiya. He is a pediatrician," she wrote in an Instagram post shared Thursday, June 18.
"His life's work has been caring for children," she continued. "He refused to abandon the babies, toddlers and children under his care during a genocide."
Earlier this week, Israel's Supreme Court rejected an appeal from the prominent Palestinian doctor, who is being held under the Unlawful Combatants Law without any criminal charges against him in Israel, according to Al Jazeera.
5 months ago
Pfizer Inc. (NYSE:PFE) is one of the
7 Best Longevity Stocks to Buy Now.
On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is now indicated in the U.S. for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors.
On June 7, 2026, Pfizer Inc. (NYSE:PFE) presented detailed Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, at the 86th Scientific Sessions of the American Diabetes **** ociation. The company said the VESPER-1, 2, and 3 studies provided proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide, showed favorable tolerability, and highlighted potential advantages from monthly delivery and a 0.5 mL injection volume.
On May 31, 2026, Pfizer Inc. (NYSE:PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 Breakwater trial. Pfizer said median progression-free survival was nearly doubled with the BRAFTOVI combination regimen versus the comparator.
7 Best Longevity Stocks to Buy Now.
On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is now indicated in the U.S. for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors.
On June 7, 2026, Pfizer Inc. (NYSE:PFE) presented detailed Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, at the 86th Scientific Sessions of the American Diabetes **** ociation. The company said the VESPER-1, 2, and 3 studies provided proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide, showed favorable tolerability, and highlighted potential advantages from monthly delivery and a 0.5 mL injection volume.
On May 31, 2026, Pfizer Inc. (NYSE:PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 Breakwater trial. Pfizer said median progression-free survival was nearly doubled with the BRAFTOVI combination regimen versus the comparator.
5 months ago
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the most undervalued stocks to invest in.
TheFly reported on May 27 that IRWD reported that the U.S. Food and Drug Administration expanded the approved use of Linzess to include pediatric patients as young as 2 years old who suffer from functional constipation. Previously, the therapy was authorized for children aged 6 years and older with the same condition. With this updated approval, Linzess can now be prescribed for patients between 2 and 5 years of age, broadening its treatment reach. The company also noted that Linzess remains the only FDA-approved prescription medication available for pediatric functional constipation, reinforcing its position as a key therapy option in this patient population.
Moreover, on May 7, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported its financial results for the first quarter of 2026, highlighting improved performance across key metrics. Total revenue reached $106.5 million, compared with $41.1 million in the same period a year earlier. Growth was primarily driven by Ironwood’s share of U.S. LINZESS net sales profits, alongside modest royalties and other income. The company also reported a significant reduction in total expenses to $33.9 million from $70.3 million year over year. GAAP net income was $40.8 million, or $0.25 per share, reversing a prior-year loss. Adjusted EBITDA rose to $76.7 million, compared to a negative result in the prior year period. Cash and liquidity positions also improved modestly.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing treatments for gastrointestinal diseases and rare disorders. It is best known for its drug LINZESS.
While we acknowledge the potential of IRWD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on May 27 that IRWD reported that the U.S. Food and Drug Administration expanded the approved use of Linzess to include pediatric patients as young as 2 years old who suffer from functional constipation. Previously, the therapy was authorized for children aged 6 years and older with the same condition. With this updated approval, Linzess can now be prescribed for patients between 2 and 5 years of age, broadening its treatment reach. The company also noted that Linzess remains the only FDA-approved prescription medication available for pediatric functional constipation, reinforcing its position as a key therapy option in this patient population.
Moreover, on May 7, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported its financial results for the first quarter of 2026, highlighting improved performance across key metrics. Total revenue reached $106.5 million, compared with $41.1 million in the same period a year earlier. Growth was primarily driven by Ironwood’s share of U.S. LINZESS net sales profits, alongside modest royalties and other income. The company also reported a significant reduction in total expenses to $33.9 million from $70.3 million year over year. GAAP net income was $40.8 million, or $0.25 per share, reversing a prior-year loss. Adjusted EBITDA rose to $76.7 million, compared to a negative result in the prior year period. Cash and liquidity positions also improved modestly.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing treatments for gastrointestinal diseases and rare disorders. It is best known for its drug LINZESS.
While we acknowledge the potential of IRWD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
9 months ago
Pediatricians' group breaks with CDC on childhood vaccine schedule
For decades, the American Academy of Pediatrics and the U.S. Centers for Disease Control and Prevention spoke with a single voice when advising the nation’s families on when to vaccinate their children.
Since 1995, the two organizations worked together to publish a single vaccine schedule for parents and healthcare providers that clearly laid out which vaccines children should get and exactly when they should get them.
Today, that united front has fractured. This month, the Department of Health and Human Services announced
For decades, the American Academy of Pediatrics and the U.S. Centers for Disease Control and Prevention spoke with a single voice when advising the nation’s families on when to vaccinate their children.
Since 1995, the two organizations worked together to publish a single vaccine schedule for parents and healthcare providers that clearly laid out which vaccines children should get and exactly when they should get them.
Today, that united front has fractured. This month, the Department of Health and Human Services announced
9 months ago
For decades, the American Academy of Pediatrics and the U.S. Centers for Disease Control and Prevention spoke with a single voice when advising the nation’s families on when to vaccinate their children.
Since 1995, the two organizations have worked together to publish a single vaccine schedule for parents and healthcare providers that clearly laid out which vaccines children should get and exactly when they should get them.
Today, that united front has fractured. Earlier this month, the Department of Health and Human Services announced drastic changes to the CDC’s vaccine schedule, slashing
Since 1995, the two organizations have worked together to publish a single vaccine schedule for parents and healthcare providers that clearly laid out which vaccines children should get and exactly when they should get them.
Today, that united front has fractured. Earlier this month, the Department of Health and Human Services announced drastic changes to the CDC’s vaccine schedule, slashing
9 months ago
U.S. vaccine panel chair questions polio recommendation for children
By Leah Douglas
WASHINGTON, Jan 23 (Reuters) - The chair of a U.S. government vaccine advisory panel questioned broad vaccine recommendations for polio and other childhood diseases and said promoting individual choice, not public health, is the key aim of the panel, drawing a rebuke on Friday from the nation's top doctors group.
Kirk Milhoan, a pediatric cardiologist who was named chair of the Centers for Disease Control and Prevention's outside Advisory Committee on Immunization Practices in December, made the comment
By Leah Douglas
WASHINGTON, Jan 23 (Reuters) - The chair of a U.S. government vaccine advisory panel questioned broad vaccine recommendations for polio and other childhood diseases and said promoting individual choice, not public health, is the key aim of the panel, drawing a rebuke on Friday from the nation's top doctors group.
Kirk Milhoan, a pediatric cardiologist who was named chair of the Centers for Disease Control and Prevention's outside Advisory Committee on Immunization Practices in December, made the comment
